新适应症-话题@MedSci

#新适应症#

62篇内容 | 2572人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416197, encodeId=d7ae141619e1e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=诺华重磅药物Jakavi欧盟收获新适应症：真性红细胞增多症（PV）, objectType=article, longId=48434, objectId=d5af48434cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d5af48434cb, replyNumber=0, likeNumber=75, createdTime=2015-03-22, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d5af48434cb, moduleTitle=诺华重磅药物Jakavi欧盟收获新适应症：真性红细胞增多症（PV）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d5af48434cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416196, encodeId=75041416196b9, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳造影剂Gadavist新适应症获FDA批准，用于两周岁以下患儿, objectType=article, longId=45126, objectId=e0a5451262d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0a5451262d, replyNumber=0, likeNumber=69, createdTime=2015-01-09, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0a5451262d, moduleTitle=拜耳造影剂Gadavist新适应症获FDA批准，用于两周岁以下患儿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0a5451262d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416195, encodeId=a41c1416195b0, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=FDA批准葛兰素史克Promacta新适应症, objectType=article, longId=39711, objectId=32dd39e1102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=32dd39e1102, replyNumber=0, likeNumber=75, createdTime=2014-08-30, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=32dd39e1102, moduleTitle=FDA批准葛兰素史克Promacta新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=32dd39e1102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416194, encodeId=dad814161945a, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, objectType=article, longId=38954, objectId=3ffd3895492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ffd3895492, replyNumber=0, likeNumber=71, createdTime=2014-08-13, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ffd3895492, moduleTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ffd3895492)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416193, encodeId=6ee7141619384, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=罗氏贝伐单抗新适应症获美国FDA快速审批, objectType=article, longId=37979, objectId=37d13e979bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37d13e979bc, replyNumber=0, likeNumber=120, createdTime=2014-07-20, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37d13e979bc, moduleTitle=罗氏贝伐单抗新适应症获美国FDA快速审批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37d13e979bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416192, encodeId=575214161921e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳多吉美（Nexavar）甲状腺癌新适应症获日本批准, objectType=article, longId=36875, objectId=dbda368e5c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbda368e5c8, replyNumber=0, likeNumber=61, createdTime=2014-06-25, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbda368e5c8, moduleTitle=拜耳多吉美（Nexavar）甲状腺癌新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbda368e5c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416191, encodeId=e2621416191dd, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准, objectType=article, longId=33005, objectId=a40633005e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a40633005e5, replyNumber=0, likeNumber=99, createdTime=2014-04-10, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a40633005e5, moduleTitle=勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a40633005e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416190, encodeId=4ec61416190ca, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=诺华单抗药索雷尔（Xolair）新适应症获欧盟批准, objectType=article, longId=31628, objectId=44263162852, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44263162852, replyNumber=0, likeNumber=83, createdTime=2014-03-09, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44263162852, moduleTitle=诺华单抗药索雷尔（Xolair）新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44263162852)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416189, encodeId=0937141618957, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳在日本提交Eylea DME新适应症申请, objectType=article, longId=31468, objectId=9003314688f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9003314688f, replyNumber=0, likeNumber=0, createdTime=2014-03-06, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9003314688f, moduleTitle=拜耳在日本提交Eylea DME新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9003314688f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416188, encodeId=736f1416188a2, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=强生抗癌药Imbruvica新适应症获FDA批准, objectType=article, longId=30690, objectId=db57306904b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db57306904b, replyNumber=0, likeNumber=60, createdTime=2014-02-18, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db57306904b, moduleTitle=强生抗癌药Imbruvica新适应症获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db57306904b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416187, encodeId=61ba141618e6a, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准, objectType=article, longId=27071, objectId=93e42e071ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93e42e071ee, replyNumber=0, likeNumber=69, createdTime=2013-11-27, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93e42e071ee, moduleTitle=拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93e42e071ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416186, encodeId=ac44141618638, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=FDA批准阿维莫泮用于术后加速恢复胃肠道功能的新适应症, objectType=article, longId=25793, objectId=59ee25e93ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ee25e93ed, replyNumber=0, likeNumber=71, createdTime=2013-10-26, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ee25e93ed, moduleTitle=FDA批准阿维莫泮用于术后加速恢复胃肠道功能的新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ee25e93ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416185, encodeId=00141416185c0, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=葛兰素史克Revolade新适应症获欧盟批准, objectType=article, longId=25020, objectId=cd2925020ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cd2925020ce, replyNumber=0, likeNumber=115, createdTime=2013-09-28, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cd2925020ce, moduleTitle=葛兰素史克Revolade新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd2925020ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416184, encodeId=6f0014161847e, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳向EMA提交Stivarga治疗GIST新适应症申请, objectType=article, longId=24123, objectId=e08c2412394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08c2412394, replyNumber=0, likeNumber=81, createdTime=2013-09-11, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08c2412394, moduleTitle=拜耳向EMA提交Stivarga治疗GIST新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08c2412394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416183, encodeId=18f414161830f, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳Eylea新适应症获欧盟批准, objectType=article, longId=23541, objectId=af4d2354129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4d2354129, replyNumber=0, likeNumber=63, createdTime=2013-09-01, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4d2354129, moduleTitle=拜耳Eylea新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4d2354129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416182, encodeId=c6f514161828c, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=拜耳Stivarga新适应症获日本批准, objectType=article, longId=23240, objectId=18f9232401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18f9232401a, replyNumber=0, likeNumber=112, createdTime=2013-08-23, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18f9232401a, moduleTitle=拜耳Stivarga新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18f9232401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416181, encodeId=26f6141618147, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=葛兰素史克Tyberb新适应症获欧盟批准, objectType=article, longId=23132, objectId=a7b72313238, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7b72313238, replyNumber=0, likeNumber=100, createdTime=2013-08-21, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7b72313238, moduleTitle=葛兰素史克Tyberb新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7b72313238)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416180, encodeId=17421416180d6, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=FDA：葛兰素史克向欧盟提交Votrient新适应症申请, objectType=article, longId=22808, objectId=15c92280847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c92280847, replyNumber=0, likeNumber=63, createdTime=2013-08-10, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c92280847, moduleTitle=FDA：葛兰素史克向欧盟提交Votrient新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c92280847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416179, encodeId=6f8014161e9ed, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=安进Xgeva骨巨细胞瘤新适应症申请获FDA批准, objectType=article, longId=20856, objectId=2774208567b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2774208567b, replyNumber=0, likeNumber=100, createdTime=2013-07-05, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2774208567b, moduleTitle=安进Xgeva骨巨细胞瘤新适应症申请获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2774208567b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416178, encodeId=8d7414161e8ba, content=<a href='/topic/show?id=a24f58e0879' target=_blank style='color:#2F92EE;'>#新适应症#</a>, objectTitle=FDA批准安进旗下狄诺塞麦骨巨细胞瘤新适应症, objectType=article, longId=20250, objectId=17e920250f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17e920250f2, replyNumber=0, likeNumber=69, createdTime=2013-06-20, rootId=0, userName=sunyl08, userId=613c3147617, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17e920250f2, moduleTitle=FDA批准安进旗下狄诺塞麦骨巨细胞瘤新适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17e920250f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

新适应症

2020-05-29

docwu2019

#新适应症#

诺华重磅药物Jakavi欧盟收获新适应症：真性红细胞增多症（PV）

2015-03-22

docwu2019

#新适应症#

拜耳造影剂Gadavist新适应症获FDA批准，用于两周岁以下患儿

2015-01-09

docwu2019

#新适应症#

FDA批准葛兰素史克Promacta新适应症

2014-08-30

docwu2019

#新适应症#

阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准

2014-08-13

docwu2019

#新适应症#

罗氏贝伐单抗新适应症获美国FDA快速审批

2014-07-20

docwu2019

#新适应症#

拜耳多吉美（Nexavar）甲状腺癌新适应症获日本批准

2014-06-25

docwu2019

#新适应症#

勃林格殷格翰抗凝血剂Pradaxa新适应症获FDA批准

2014-04-10

docwu2019

#新适应症#

诺华单抗药索雷尔（Xolair）新适应症获欧盟批准

2014-03-09

sunyl08

#新适应症#

拜耳在日本提交Eylea DME新适应症申请

2014-03-06

sunyl08

#新适应症#

强生抗癌药Imbruvica新适应症获FDA批准

2014-02-18

sunyl08

#新适应症#

拜耳多吉美（Nexavar）新适应症用于分化型甲状腺癌获FDA批准

2013-11-27

sunyl08

#新适应症#

FDA批准阿维莫泮用于术后加速恢复胃肠道功能的新适应症

2013-10-26

sunyl08

#新适应症#

葛兰素史克Revolade新适应症获欧盟批准

2013-09-28

sunyl08

#新适应症#

拜耳向EMA提交Stivarga治疗GIST新适应症申请

2013-09-11

sunyl08

#新适应症#

拜耳Eylea新适应症获欧盟批准

2013-09-01

sunyl08

#新适应症#

拜耳Stivarga新适应症获日本批准

2013-08-23

sunyl08

#新适应症#

葛兰素史克Tyberb新适应症获欧盟批准

2013-08-21

sunyl08

#新适应症#

FDA：葛兰素史克向欧盟提交Votrient新适应症申请

2013-08-10

sunyl08

#新适应症#

安进Xgeva骨巨细胞瘤新适应症申请获FDA批准

2013-07-05

sunyl08

#新适应症#

FDA批准安进旗下狄诺塞麦骨巨细胞瘤新适应症

2013-06-20